{"id":18453,"date":"2025-07-30T19:09:40","date_gmt":"2025-07-30T17:09:40","guid":{"rendered":"https:\/\/www.fondationpierrefabre.org\/?post_type=avada_portfolio&p=18453"},"modified":"2025-11-23T18:16:26","modified_gmt":"2025-11-23T17:16:26","slug":"operational-study-on-early-detection-and-treatment-of-sickle-cell-disease","status":"publish","type":"avada_portfolio","link":"https:\/\/www.fondationpierrefabre.org\/en\/programmes\/operational-study-on-early-detection-and-treatment-of-sickle-cell-disease\/","title":{"rendered":"Operational study on early detection and treatment of sickle cell disease"},"content":{"rendered":"

Operational study on early detection and treatment of sickle cell disease<\/h1>\n

\u2014 Senegal \u2014<\/span><\/em><\/h3>\n<\/div>
<\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div>
<\/span><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div>
<\/div>
<\/div>
<\/div>

BACKGROUND<\/strong><\/span><\/p>\n<\/div>\n

<\/div>
<\/div>
<\/div>

Each year in Africa, 1% of newborns carry the sickle cell trait, meaning 350,000 children. Without swift and appropriate care, half of them may die from complications generated by the disease. Since 2006, the WHO has recommended neonatal screening and early treatment of sickle cell disease to effectively combat this affliction.<\/p>\n

In 2013, due to the severity of these needs, the University Gaston Berger in Saint-Louis, Senegal, decided to launch a broad operational study under the leadership of Professor Ibrahima Diagne. The objectives were to measure the benefits of systematic neonatal screening and early treatment, assess and approve ad hoc protocols, and develop a model that could be used across the country and beyond.<\/strong> The University chose to call upon the Malian experience of Fondation Pierre Fabre to accomplish these goals. The Foundation, excited about the project\u2019s scope, agreed to a six-year partnership.<\/p>\n

Both institutions therefore opened a testing and analysis laboratory at the University<\/strong>: every year, 6,000 newborns in the maternity ward at the Saint-Louis Regional Hospital and a medical centre on the city\u2019s outskirts are screened. An outpatient support unit to help sick children is also being created.<\/strong> Meanwhile, the local medical and paramedical staff are trained in diagnosis and management of the disease and the broader population, more specifically pregnant women, are being educated on the need for neonatal screening. Once the study is completed, children will continue to be monitored until the age of fifteen.<\/p>\n

For Fondation Pierre Fabre, this operational study is important in more ways than one. First, it accomplishes a twofold mission by combining healthcare with research<\/strong>. Second, it serves as the basis for an innovative model in line with Senegal\u2019s needs and means. Lastly, it promotes an approach belonging to African scientists, which is a powerful argument in light of the fact that 80% of sickle cell disease research is performed in the North, while 80% of those afflicted with the disease are in the South.<\/p>\n

In 2019, an article was published as part of this study on a health information system for data management of the blood sampling from the newborn at the maternity wards and the disease screening at the Center for Research and Ambulatory Care of the Sickle Cell Disease (CERPAD).
\nTowards an Information System for Sickle Cell Neonatal Screening in Senegal,<\/a>
\n<\/em>Diallo A.H., Camara G., Lamy J.B., Lo M., Diagne I., Makalou D., Diop M., Doupa D. <\/em>
\nStud Health Technol Inform 2019 258: (95-99)<\/em><\/p>\n<\/div>

<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div>

KEY FACTS<\/span><\/strong><\/span>
\n_____<\/span><\/p>\n

Priority<\/strong><\/span>
\nCombating Sickle cell disease<\/span><\/p>\n

Programme<\/strong><\/span><\/p>\n

Since 2013<\/span><\/p>\n

Type of involvement<\/strong><\/span>
\nDistributor and operator<\/span><\/p>\n

Actions<\/strong><\/span><\/p>\n